n (%) | Daclizumab 150 mg SC |
---|---|
Any serious infectiona (n = 410) | 13 (3) |
Pneumonia | 3 (<1) |
Urinary tract infection | 3 (<1) |
Bronchitis | 2 (<1) |
Clostridium difficile colitis | 1 (<1) |
Diverticulitis | 1 (<1) |
Gastrointestinal infection | 1 (<1) |
Hepatitis C | 1 (<1) |
Infectious mononucleosis | 1 (<1) |
Upper respiratory tract infection | 1 (<1) |
Any serious cutaneous AEb (n = 410) | 8 (2) |
Urticaria | 2 (<1) |
Allergic dermatitis | 1 (<1) |
Erythrodermic psoriasis | 1 (<1) |
Photodermatitis | 1 (<1) |
Psoriasis | 1 (<1) |
Stevens-Johnson syndromec | 1 (<1) |
Toxic skin eruption | 1 (<1) |
Any serious hepatic AEd (n = 410) | 5 (1) |
Hepatic enzyme increased | 3 (<1) |
Autoimmune hepatitis | 1 (<1) |
Gamma-glutamyltransferase increased | 1 (<1) |
Hepatic laboratory abnormalities (n = 409) | |
ALT or AST | |
≥3 × ULN | 37 (9) |
>5 × ULN | 18 (4) |
>10 × ULN | 11 (3) |
Elevation in ALT or AST ≥3 × ULN with concurrent total bilirubin >2 × ULN | 2 (<1)e |